Zu den Inhalten springen

Translational Vascular Medicine

Projektleiter: Prof. Dr. Christoph Hehrlein

Professor Dr. Christoph Hehrlein
Cardiology and Angiology I
Head, Interdisciplinary Vascular Center,
Heart Center, University of Freiburg
Breisacher Str. 33
79106 Freiburg, Germany

Phone: 0049 761 270 77090
Fax: 0049 761 270 32540
E-Mail: christoph.hehrlein@universitaets-herzzentrum.de

Our research group specializes in molecular and basic science models of clinically relevant topics. Our team is interested, for instance, in developing methods to predict and prevent recurrence of stenotic lesions after catheter interventions.

We have previously evaluated modifications of thrombectomy devices, stents and balloons delivering drugs to the vessel wall, and we have created new methods of ultrasound analysis in vascular medicine.

We are focusing our science momentarily on biocompatibility studies of novel biodegradable and resorbable materials such as biopolymers (i.e. PGLA) or trace elements such as magnesium or zinc potentially useful for the manufacture of vascular stents or stent grafts.

Our research is funded by grants from the BMBF (Bundesministerium für Bildung und Forschung), Germany. We are constantly looking for new, enthusiastic doctorates and postgraduate students eager to learn basic sciences from “bench to bedside”.

A “core” research team of 2 lab managers is installed at our laboratory to ensure optimal services in developing technical skills of its team members. A variety of standard basic science operations such cell cultures, fluorescence microscopy, Western blot and PCR - just to name some - can be learned at our laboratory.

Please inform yourself about us from previous doctorates (alumni). The group leader is proud of having accomplished a successful guidance of so many doctorates to their PhD degrees (Dr. med, Dr. rer. nat)

Discover the world of science. We look forward to working with you!

These images tell a story and we will explain it to you…..

Prof. Dr. Christoph Hehrlein

Prof. Dr. Christoph Hehrlein
Group leader

E-Mail: christoph.hehrlein@uniklinik-freiburg.de

Dr. med. Amina Arab

Dr. med. Amina Arab
Lab Manager

E-Mail: amina.arab@uniklinik-freiburg.de
Tel.: +49 (0) 761 270 70090
Fax.:+49 (0) 761 270 70060

Nadia Kress, MS

Nadia Kress, MS
Lab Manager

E-Mail: nadia.kress@uniklinik-freiburg.de
Tel.: +49 (0) 761 270 70090
Fax.:+49 (0) 761 270 70060

External
Prof. Dr. Ralf Kinscherf

Prof. Dr. Ralf Kinscherf
Anatomie und Zellbiologie 
Universität Marburg

Dr. med. Jin Wang

Dr. med. Jin Wang
Common Health Institute
Peking, China

Prof. Dr. Jörg Haberstroh

Prof. Dr. Jörg Haberstroh
Experimentelle Chirurgie 
Universität Freiburg

Dr. Kristin Werner

Dr. Kristin Werner
Pathologie
Universität Freiburg

Dr. Ornelle Sandra Fosso

Dr. Ornelle Sandra Fosso
Kinderklinik
Universität Freiburg

Internal

  • Dr. Heiko Bugger
  • PD Dr. Daniel Dürschmied 
  • PD Dr. Ingo Ahrens 
  • Prof. Dr. Constantin von zur Mühlen

Mentors

  • Prof. Dr. Wolfgang Kübler, Neckargemünd, Deutschland
  • Prof. Dr. Christoph Bode, Freiburg, Deutschland
  • Prof. Dr. Eberhard Ritz, Heidelberg, Deutschland  
  • Prof. Dr. Tim A. Fischell, Kalamazoo, Michigan, USA
  • Prof. Dr. Robert H. Svenson, Charlotte, North Carolina USA
  • Prof. Dr. Francis Robiscek, Charlotte, North Carolina, USA
  • Prof. Dr. Eberhard Zeitler (Ɨ), Nürnberg, Deutschland
  • Prof. Dr. Dieter Raithel, Nürnberg, Deutschland

Markus Zimmermann, Marc Stintz, Klaus Dönges, Christina Gollan, Ines Weinschenk, Simone Kaiser, Marc Kollum (together with C. Bode and W. Kübler).

Jin Wang, Elisabeth Rink, Ralf Schreiber, Dorothee Harder, Philipp Maletzki, Sophia Kersting, Johanna Hummel, Kathrin Bausch, Katharina von Schmädel, Isabel Eisser (Dr. rer nat.), Lisa Hospes, Jutta Löffler (Dr. rer. nat), Ornelle Sandra Fosso, Kathrin Schauwecker

Peer-Reviewed Publications of Doctorate’s Thesis (Students as First-authors only)

Kersting S, Grumann T, Hummel J, Hauschke D, Bode C, Hehrlein C: Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. Crit Pathw Cardiol. 2012 Sep;11(3):152-9.

Duerschmied D*, Maletzki P*, Freund G, Olschewski M, Bode C, Hehrlein C. Success of arterial revascularization determined by contrast ultrasound muscle perfusion imaging. J Vasc Surg. 2010 Dec;52(6):1531-1536

Rink E, Dürschmied D, Harder D, Zhou Q, Freund G, Hehrlein C: Contrast enhanced ultrasound perfusion imaging- a new method. Bildverarbeitung für die Medizin 2006; Ed. Handels H, Ehrhard J, Springer Verlag Berlin , pp 454-458

Kollum M, Kaiser S, Kinscherf R, Metz J, Kübler W, Hehrlein C: Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler Thromb Vasc Biol 1997; 91: 698-704

*Equally contributed

2014

1. Toelg R, Merkely B, Erglis A, Hoffman S, Bruno H, Kornowski R, Slagboom T, Naber C, Witzenbichler B, Graf K, Richardt G, Hehrlein C; DELUX investigators. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry. EuroIntervention.
2014 Sep;10(5):591-9. doi: 10.4244/EIJV10I5A102. [PubMed]

2. Witsch T, Mauler M, Herr N, Stallmann D, Bode C, Hehrlein C, Duerschmied D. A novel hollow and perforated flexible wire allows the safe and effective local application of thrombolytic therapy in a mouse model of deep vein thrombosis. J Thromb Thrombolysis. 2014 May;37(4):450-4. doi: 10.1007/s11239-013-1013-x. [PubMed]

2013

3. Machaalany J, Bilodeau L, Hoffmann R, Sack S, Sievert H, Kautzner J, Hehrlein C, Serruys P, Sénéchal M, Douglas P, Bertrand OF. Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. Am Heart J. 2013 May;165(5):761-9. doi: 10.1016/j.ahj.2013.01.010. Epub 2013 Feb 14. [PubMed]

2012

4. Hehrlein C, Dietz U, Kubica J, Jørgensen E, Hoffmann E, Naber C, Lesiak M, Schneider H, Wiemer M, Tölg R, Richardt G: Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial. Cardiovasc Revasc Med. 2012 Sep-Oct;13(5):260-4. doi: 10.1016/j.carrev.2012.06.002. Epub 2012 Aug 4. [PubMed]
  
5. Kersting S, Grumann T, Hummel J, Hauschke D, Bode C, Hehrlein C: Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents. Crit Pathw Cardiol. 2012 Sep;11(3):152-9. [PubMed]
  
6. Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Möllmann H, Hehrlein C, Ouarrak T, Senges J, Meinertz T; German Transcatheter Mitral Valve Interventions (TRAMI) investigators: MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail. 2012 Sep;14(9):1050-5. Epub 2012 Jun 8. [PubMed]

7. Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Speck U, Böhm M, Cremers B: Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv. 2012 Mar;5(3):323-30. [PubMed]
  
8. Riemekasten G, Hoffmann U, Sunderkötter C, Weiss N, Kuhn A; angiologisch-dermatologisch-rheumatologische DU-Expertenboard: Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr. 2012 Jan;137(1-2):34-40. Epub 2011 Dec 16. Review. [PubMed]

2011

9. Hehrlein C: STEMI Therapy: Normoxic reperfusion is not good enough. Catheter Cardiovasc Intervent 2011, Mar 1;77(4):483. doi: 10.1002/ccd.22984. 10. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys PW. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011 Feb;6(7):805-812 [PubMed] 

10. Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys PW. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011 Feb;6(7):805-812
[PubMed]

2010

11. Hehrlein C: Quantitative myocardial blush grade: prepped for a core lab standardization. Catheter Cardiovasc Interv. 2010 Oct 1;76(4):511-2.20882654. [PubMed]

12. Duerschmied D, Maletzki P, Freund G, Olschewski M, Bode C, Hehrlein C. Success of arterial revascularization determined by contrast ultrasound muscle perfusion imaging. J Vasc Surg. 2010 Dec;52(6):1531-1536 [PubMed]

13. Kastrati A, Balducelli M, Di Sciascio G, Moccetti T, Bortone AS, Colombo A, Waltenberger J, Hehrlein C; MAR-Ty(n) Investigators. A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients withde novo coronary artery lesions: study design and protocol. EuroIntervention.2010 Apr;5(8):976-80. : [PubMed] 

14. Arab A, Wang J, Bausch K, von Schmädel K, Bode C, Hehrlein C: Transient hyperoxic reoxygenation reduces cytochrome C oxidase activity by increasing uperoxide dismutase and nitric oxide. J Biol Chem. 2010 Apr 9;285(15):11172-7. [PubMed] 

2009

15. Duerschmied D, Zhou Q, Rink E, Harder D, Freund G, Bode C, Hehrlein C: Simplified contrast ultrasound accurately reveals muscle perfusion deficits and reflects collateralization in peripheral arterial disease. Atherosclerosis 2009; 202: 505-12 [PubMed]

16. Hansi C, Arab a, Rzany A, Ahrens I, Bode C, Hehrlein C: Difference of platelet adhesion on amorphous slicon carbide, magnesium, stainless steel and cobalt chromium stent surfaces. Catheter Cardiovasc Intervent 2009; 73: 488-496 [PubMed]

2008

17. Hehrlein C: Through the back door - retrograde stenting in chronic total occlusions. Catheter Cardiovasc Interv. 2008; 72: 370 [PubMed]

18. Arab A, Kümmerer K, Wang J, Bode C, Hehrlein C: Oxygenated perfluorochemicals improve cell survival during reoxygenation by pacifying mitochondrial activity. J Pharmocol Exp. Ther 2008; 325: 417-424 [PubMed]  

19. Duerschmied D, Maletzki P, Freund G, Seufert J, Bode C, Hehrlein C: Analysis of muscle microcirculation in advanced diabetes mellitus by contrast enhanced ultrasound. Diabetes Res Clin Pract. 2008; 81: 88-92 [PubMed]

20. Scheller B, Hehrlein C, Boksch W, Rutsch W, Hashi D, Dietz U, Boehm M, Speck U: Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2008; 97: 773-81 [PubMed] 

21. Stuplich J, Freund G, Bode C, Hehrlein C: Ultrasound guided thrombin injection in pseudoaneurysm. Clin Res Cardiol 2008; 97: Suppl 3: 76 [PubMed]
 
22. Grumann T, Hummel J, Kersting S, Bode C, Hehrlein C: Does DES Implantation saves lifes in STEMI patients? Result from the Freiburg Stent Registry (FRIST). E Hear J 2008; 87: Suppl 2: 115  [PubMed]

23. Stuplich, J, Freund G, Dürschmied D, Zhou Q, Richter S, Macharzina R, Bode C, Hehrlein C: Therapie des iatrogenen Aneurysma spurium durch ultraschallgesteuerte perkutane Thrombininjektion. Vasa 2008; 37, Suppl 2: 95

24. Macharzina R, Freund G, Bode C, Hehrlein C: Novel static 3D ultrasonography for plaque characterization. Vasa 2008; 37, Suppl 2: 80

2007

25. Kollum M, Hoefer I, Schreiber R, Bode C, Hehrlein C: Systemic application of anti- ICAM-1 monoclonal antibodies to prevent restenosis in rabbits: an anti-inflammatory strategy. Coronary Artery Dis 2007; 18: 117-123 [PubMed]

26. Freund G, Dürschmied D, Zhou Q, Richter S, Macharzina R, Haas R, Becherer A, Bode C, Hehrlein C: Occlusion of iatrogenic pseudoaneurysm with percutaneous ultrasound guided thrombin injection. Vasa 2007; 36: 96-99 [PubMed]

27. Hehrlein C: Promises of biodegradable stents. Catheter Cardiovasc Intervent 2007; 69: 739 [PubMed]

28. Hehrlein C: Dual drug release from stents - Will we be happy with thing one and thing two. Catheter Cardiovasc Intervent 2007; 70: 880 [PubMed]

2006

29. Grumann T, Arab A, Bode C, Gutenberger R, Hehrlein C: Reoxygenation of hypoxic coronary smooth muscle cells suppresses hypoxia inducible factor 1 α gene expression and augments radiation induced apoptosis. Strahlenther Onkol 2006; 182: 16-21 [PubMed]

30. Dürschmied D, Olson L, Rossknecht A, Freund G, Bode C, Hehrlein C: Contrast ultrasound perfusion imaging of lower extremities in peripheral arterial disease- A novel diagnostic method. Eur Heart J 2006; 27: 310-315 [PubMed]

31. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U: Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. New Engl J Med 2006; 355: 2113-2124 [PubMed]

32. Zhou Q, Duerschmied D, Harder D, Rink E, Bode C, Hehrlein C: Contrast ultrasound perfusion imaging: The beginning of a new era in the diagnostic of peripheral artery disease? J Am Coll Cardiol 2006; 67: 117 [PubMed]

33. Rink E, Dürschmied D, Harder D, Zhou Q, Freund G, Hehrlein C: Contrast enhanced ultrasound perfusion imaging- a new method. Bildverarbeitung für die Medizin 2006; Ed. Handels H, Ehrhard J, Springer Verlag Berlin , pp 454-458 [PubMed]

34. Duerschmied D, Zhou Q, Olscheswki M, Harder D, Rink E, Bode C, Hehrlein C: Contrast ultrasound perfusions imaging is superior to ancle-brachial index in the diagnosis of peripheral arterial disease. Circulation 2006; 42: 117 [PubMed]

35. Hehrlein C, Rink E, Harder D, Dürschmied D, Bode C: A novel method to quantify muscle perfusion with CEUS. Int Angiol 2006; 25: 55. [PubMed]

2005

36. Rink E, Dürschmied D, Harder D, Olschweski M, Hehrlein C: Perfusionsmessung der Wadenmuskulatur mit CEUS.Vasa 2005;34: 18-19

37. Hehrlein C: Radioactive Stents. In: Local Drug Delivery for Coronary Artery Disease. Established and Emerging Concepts (eds. E. Camenzind and I. K. De Scheerder), Taylor and Francis, London and New York; 2005; pp 163-170

38. Hehrlein C, Bode C: Coronary Radiation Therapy for the Prevention of Restenosis. In: Clinical, Interventional and Investigational Thrombocardiology (eds. Richard C. Becker and Robert A. Harrington), Taylor and Francis, London and New York 2005; pp 555-561
  
39. Kollum M, Farb A, Schreiber R, Arab A, Geist A, Wnendt A, Grandt A, Virmani R, Bode C, Hehrlein C: Particles debris from a nanoporous stent coating obscures potential benefitial effects of tacrolimus eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005; 64: 85-90 [PubMed]

40. Duerschmied D, Olson L, Rossknecht A, Freund G, Bode C, Hehrlein C: Contrast ultrasound perfusion imaging of lower extremities in peripheral arterial disease- a novel diagnostic method. Eur Heart J 2005; Suppl 4: 405 [PubMed]

2004

41. Grumann T, Scheller A, Van de loo A, Bode C, Hehrlein C: In-Stent order In-Segment. Wo befindet sich die Restenose nach Implantation von Sirolimus beschichteten Stents? Z Kardiol 2004; 93; Suppl 3: 203

42. Grumann T, Scheller A, Van de loo A, Bode C, Hehrlein C: Quantitative Koronaranalyse des Cypher-Stents im akuten Koronarsyndrom. Z Kardiol 2004; 93; Suppl 3: 32 [PubMed]

43. Schreiber R, Kollum M, Bode C, Hehrlein C: Anti-ICAM 1 Antikörper abhängige Expressionshemmung von bFGF verhindert nicht die Restenose nach PTCA. Z Kardiol 2004; 93; Suppl 3: 203

44. Arab A, Grumann T, Guttenberger R, Bode C, Hehrlein C: Reoxygenation of hypoxic coronary smooth muscles cells amplifies growth retarding effects of ionizing irradiation. Circulation 2004; 109: 1036-1040 45. Hehrlein C: Radioactive Stents: Still in memory? Catheter Cardiovasc Interv 2004; 61: 326 [PubMed]

2003 

46. Hehrlein C: Brachytherapy. Center or not Center. Catheter Cardiovasc Interv 2003; 60: 258

47. Hehrlein C: Brachytherapy in total coronary occlusion: Quidquid agis, prudenter agas, et respice finem. Catheter Cardiovasc Interv 2003; 58: 330

48. Arab A,Grumann T, GuttenbergerR, Bode C, Hehrlein C: Reoxygenierung von hypoxischen glatten Muskelzellen reduziert die mRNA Expression von VEGF nach Strahlentherapie. Z Kardiol 2003; 92; Suppl 1: 43

2002

49. Hehrlein C, DeVries JJ, Haller SD, Arab A, Foster MJ, Fischell TA: Role ot the “dogbone” effect of balloon expandable stents: Different performance characteristics of the Duet and NIR stents and stent delivery systems. J Invas Cardiol 2002; 14: 59-65 [PubMed]


50. Sick P, Bosteneau O, Niebauer J, Hehrlein C, Schuler G: Neointima formation after stent implantation in an experimental model of restenosis: PTFE covered vs. uncovered stainless steel stents. Heart Disease 2002; 4: 18-25 [PubMed]

51. Hehrlein C: Intracoronary radiation. Are the “frequent flyer” still around? Catheter Cardiovasc Interv 2002; 55: 237-238 [PubMed]

52. Hehrlein C: Radioaktive Stents-Probleme und Lösungsmöglichkeiten. Herz: 2002; 27: 17-22 53. Silber S, Baumgart D, Hehrlein C, Meinertz T, Mügge A, Rutsch W, vom Dahl J: The IST Registry. Z Kardiol 2002; 91: Suppl lII, 33-39 54. Hehrlein C, Bode C: Neue Stents überraschen. Herzstiftung 2002; 2-5 [PubMed]

53. Silber S, Baumgart D, Hehrlein C, Meinertz T, Mügge A, Rutsch W, vom Dahl J: The IST Registry. Z Kardiol 2002; 91: Suppl lII, 33-39

54. Hehrlein C, Bode C: Neue Stents überraschen. Herzstiftung 2002; 2-5 [PubMed]

55. Hehrlein C, Arab A, Bode: Drug eluting stent. The “magic bullet” for prevention of restenosis? Bas Res Cardiol 2002; 97: 417-423 [PubMed]

56. Hehrlein C: Is radioangioplasty next? Catheter Cardiovasc Interv 2002; 57:295-296 [PubMed]

57. Hehrlein C: Novel Concepts for Radioactive Stents. In: Vascular Brachytherapy 3rd edition (ed. R. Waksman) 2002; pp 389-395

58. Hehrlein C: The Radioactive Balloon. In. Vascular Brachytherapy 3rd edition (ed. R. Waksman) 2002;
pp 811-817

59. Kollum M, Hehrlein C: Neue Erkenntnisse zur Gefäßthrombose und Kanteneffekt nach vaskulärer Brachytherapie. In: Kardiovaskuläre Strahlentherapie-Ein multidisziplinäres Lehrbuch 2. Auflage (C. Hehrlein, Hrsg.) 2002, Steinkopff Vrl; pp 75-85 [PubMed]

60. Hehrlein C: Strategien zur Verhinderung der Restenose nach Katheterintervention. In: Kardiovaskuläre Strahlentherapie- ein multidisziplinäres Lehrbuch 2. Auflage (C. Hehrlein, Hrsg.) 2002; Steinkopff; pp 13-31
[PubMed]

61. Beschorner U, Kollum M, Haberstroh J, Schreiber R, Virmani R, Farb A, Wnendt S, Bode C, Hehrlein C: Wirkung eines neuen Tacrolimus freistetzenden nanoporotischen Stents im Schweinemodell. Z Kardiol 2002; 91, Suppl 5: 66

2001

62. Hehrlein C, DeVries JJ, Wood TA, Arab A, Kloostra A, Lauer MA, Fischell TA: Overestimation of Duet and NIR stent delivery balloon diameters by manufacturers‘ compliance tables. A quantitative coronary analysis of Duet and NIR stent implantation.Catheter Cardiovasc Interv 2001; 53: 474-478 [PubMed]

63. Hehrlein C, DeVries JJ, Arab A, Haller SD, Schloesser K, Tio FO, Fischell TA: Failure of a novel gamma emitting radioisotope stent (Pd-103) to prevent edge effects. Circulation 2001; 104: 2358-2362 [PubMed]

64. Hansen A, Hehrlein C, Hardt S, Bekerdjian R, Brachmann J, Kübler W, Bode C, Kücherer H: Is the “candy wrapper” effect of 32P radioactive ?-emitting stents due to remodeling or neointima hyperplasia? Insights from intravascular ultrasound. Catheter Cardiovasc Interv 2001; 54:41-48 (IF: 1, 5)

65. Hehrlein C, Bode C: Koronarintervention ohne Restenose -Vision oder Märchen? PTCA Aktuell 2001; 16: 15-19

66. Arab A, Bode C, Hehrlein C: Radioactive stents-Any chance for a resurrection? Eur Heart J 2001; 22: 1245-1247 [PubMed]

67. Hehrlein C, Wolf GK, Kovacs A: Porous metallic stent with a ceramic coating. Patentanmeldung EP 1319416 A (2001). Verfahren zur porösen Oberflächen-veränderung von Koronarstents mit dem Ziel der Medikamentenfreisetzung und der beschleunigten Reendothelialisierung sowie Hemmung der Restenoseentwicklung.

68. Hehrlein C, Wolf GK, Kovacs A: Oxygen delivery source. Patentanmeldung US 38468 (2001). Kathetervermittelte Verfahren zur lokalen hyperoxämischen Reoxygenierung im akuten Myokardinfarkt.

69. Hehrlein C, Wolf GK, Kovacs A: Delivery source of oxygen and kit for producing a medical device. Patentanmeldung EP 1325 756 A2 (2001): Installationsverfahren zur lokalen hyperoxämischen Reoxygenierung in der interventionellen Kardiologie durch Kathetermodifikation und in der Herz-und Gefäßchirurgie durch Graftmodifikation.

70. Kollum M, Cottin Y, Chan RS, Vodovotz Y, Waksman R, Hehrlein C: Verringerte adventitielle Neovaskularisation im Restenosemodell des Schweins. Z Kardiol 2001; Suppl 2 : 295

71. Kollum M, Cottin Y, Chan RS, Vodovotz Y, Waksman R, Hehrlein C: Therapie der In-Stent Restenose mit einem 32P-Stent im Schweinemodell. Z Kardiol 2001; Suppl.2: 668

72. Kollum M, Cottin Y, Chan RS, Virmani R, Vodovotz Y, Waksman R, Hehrlein C: Verzögerte Reendothelialisierung und vermehrt Apoptose von T-Zellen nach intrakoronarer Strahlentherapie. Z Kardiol 2001; Suppl 2: 964 73. Hehrlein C, Bode C: Koronarintervention ohne Restenose-Vison oder Märchen PTCA Aktuell 2001; 16: 15-19 74. Arab A, Bode C, Hehrlein C: Radioactive stents-Any chance for a resurrection? Eur Heart J 2001; 22: 1245-1247 75. Dietz R, Silber S, Baumgart D, Hehrlein C, Tebbe H: Leitlinien und Empfehlungen. Positionspapier zur intrakoronaren Brachytherapie Z Kardiol 2001; 90: 875-880

73. Hehrlein C, Bode C: Koronarintervention ohne Restenose-Vison oder Märchen PTCA Aktuell 2001; 16: 15-19

74. Arab A, Bode C, Hehrlein C: Radioactive stents-Any chance for a resurrection? Eur Heart J 2001; 22: 1245-1247

75. Dietz R, Silber S, Baumgart D, Hehrlein C, Tebbe H: Leitlinien und Empfehlungen. Positionspapier zur intrakoronaren Brachytherapie Z Kardiol 2001; 90: 875-880

2000

76. Hehrlein C, Kovacs A, Yue N, Nath R, Wolf GK: A novel angioplasty catheter impregnated with beta-particle emitting radioisotopes for vascular brachytherapy to prevent restenosis. First in vivo results. Eur Heart Journal 2000; 21: 2056-2062

77. Fischell TA, Hehrlein C, Fischell RE, Fischell DR: The impact of stent design and delivery upon the long-term efficay of radioisotope stents. J Invas Cardiol 2000; 12: 162-167

78. Hehrlein C: Update on radioactive stents. Vasc Radiotherapy Mon 2000; 3: 31-35 79.

79. Hehrlein C, Bode C: Koronarintervention ohne Restenose-Vison oder Märchen. PTCA Aktuell 2001;
16: 15-19

80. Hehrlein C: Strategien zur Verhinderung der Rezidivstenose nach Katheterintervention. In: Kardiovaskuläre Strahlentherapie-Ein multidisziplinäres Lehrbuch (ed. C. Hehrlein), Steinkopff Verlag Darmstadt 2000; pp 13-31

81. Fischell TA, Hehrlein C: Radioaktive Stents- Erste Ergebnisse aus Amerika und Hehrlein, Hrsg.) In: Kardiovaskuläre Strahlentherapie-Ein multidisziplinäres Lehrbuch (C. Hehrlein, Hrsg.),Steinkopff Verlag Darmstadt 2000; pp 131-154

1999

82. Hehrlein C, Kaiser S, Riessen R, Metz J, Fritz P,Kübler W: External beam radiation after stent implantation increases neointimal hyperplasia by augmenting smooth muscle cell proliferation and extracellular matrix accumulation. J Am Coll Cardiol 1999; 34: 561-566

83. Hehrlein C, Weinschenk I, Metz J: Long period of balloon inflation and the implantation of stents potentiate smooth muscle cell death. Role of chronic vascular injury. Int J Cardiovasc Interventions 1999; 2: 21-26

84. Hehrlein C, Kollum M, Arab A, Kamencic H, Metz J: Increased apoptotic cell death in the neointima after stent-based vascular irradiation. Role of radiation-induced apoptosis for restenosis reduction. J Intervent Cardiol 1999; 12: 299-304

85. Yue N, Nath R, Hehrlein C: Dosimetry of a novel balloon angioplasty catheter for vascular brachytherapy. Cardiovasc Radiat Med 1999; 4: 349-357

86. Fischell T.A., Hehrlein C: Radiation with stent-based systems. Cur Intervent Cardiol Reports 1999; 1: 36-42

87. Hehrlein C, Fischell TA: History of the radioisotope stent. Vasc Radiotherapy Mon 1999; 1: 66-70

88. Schweickert H, Fehsenfeld P, Kleinrahm A;Schlösser K, Hehrlein C: Radioactive stents. Min Invas Technologies (MITAT) 1999; 8: 255-260

89. Fischell TA, Fischell DR, Carter AJ, Hehrlein C, Fischell RE : Radioisotope Stents. In: Handbook of Stents (ed. P.W. Serruys), 1999; pp 156-165
  
90. Fischell T.A., Hehrlein C: Radiation with stent-based systems. In: Interventional Cardiology (ed. D.R. Holmes), 1999; pp 23-26

91. Hehrlein C, Wolf GK: Catheter or vessel support with radiation sensitizer and corresponding production method. Patent WO 9956828 (1999): Verfahren zur Beschichtung eines radioaktiven Ballon-Katheters mit einer sauerstoffhaltigen Oberfläche zur vermehrten Freisetzung von Sauerstoffradikalen.

92. Hehrlein C, Hardt S, Hansen A, Bode C, N.Weissman, Popma J: Langzeitergebnisse der Heidelberger Pilotsstudie mit radioaktiven Stents zur Verhinderung der Restenose bei Patienten nach PTCA. Z Kardiol 1999; 87: Suppl 2: 784

93. Hehrlein C, DeVries JJ, Haller SD, Kloostra A, Foster M, Fischell TA: Acute Performance Characteristics of DUET vs NIR Stents and Stent Delivery Systems. Am J Cardiol 1999; 84: 110

94. Hehrlein C, DeVries JJ, Wood TA, Bedi N, Kloostra A, Foster M, Fischell TA: Overestimation of stent delivery balloon diameter by manufacturers' compliance tables: A QCA analysis of DUET and NIR stent implantation. Circulation 1999; 100: 293

1998

95. Fehsenfeld P, Golombeck M, Kleinrahm A, Schlösser K, Schüssler B, Schweickert H, Hehrlein C: On the production of radioactive stents. Sem Intervent Cardiol 1998; 3: 157-161

96. Hehrlein C: The radioisotope stent- what did we learn from pre-clinical trials? Int J Cardiovasc Interventions 1998; 1: 77-80

97. Hehrlein C, Bode C, Brachmann J, Kübler W: Prävention und Behandlung der Restenose. Hauptvortrag anläßlich der 63. Jahrestagung der Deutschen Gesellschaft für Kardiologie, Mannheim, April 1997. Z Kardiol 1998; 87: 126-130

98. Hehrlein C, Brachmann J, Bode C, Kübler W: Kathetergestützte Verfahren zur Verringerung der Restenose nach Angioplastie. Hauptvortrag im Rahmen des Symposiums ‘Chronische Myokardischämie’, Düsseldorf, September 1997. Z Kardiol 1998; 87, Suppl 2: 166-170

99. Hehrlein C: Radioactive stents- European experience. In: Vascular Brachytherapy. 2nd edition (ed. R. Waksman), Futura Publishing, Inc. 1998; pp 333-343

100. Hehrlein C, Wolf GK: Katheter und Gefäßstütze zur kombinierten Strahlen-und Medikamententherapie. Patent DE 198 12 426 (1998): Beschichtungsverfahren eines Ballon-Katheters zur Medikamentenfreisetzung und lokaler Bestrahlung.

101. Hehrlein C, Kollum M, Kamencic H, Metz J: Programmierter Zelltod (Apoptose) in der Neointima des Kaninchens nach Implantation von radioaktiven Stents. Z Kardiol 1998; 86 : Suppl.2: 835

102. Hehrlein C, Hardt S, Brachmann J, Kübler W, Bode C, Weissman N, Popma J: P-32 stents for the prevention of restenosis. Results from the Heidelberg safety trial using the Palmaz-Schatz stent design at moderate activity levels in patients with restenosis after PTCA. Circulation 1998; 98: Suppl 1: 780 1997

103. Kollum M, Kaiser S, Kinscherf R, Metz J, Kübler W, Hehrlein C: Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler Thromb Vasc Biol 1997; 91: 698-704

104. Hehrlein C, Kübler W: Advantages and limitations of radioactive stents. Sem Intervent Cardiol 1997; 2: 109-113

105. Hehrlein C, Bode C, Kübler W: Prävention der Restenose nach perkutaner transluminaler Koronarangioplastie (PTCA). Fibrinolyse 1997; 1: 9-12

106. Hehrlein C, Kovacs A, Löscher F, Seeger S, Wolf GK: Novel radioisotope coated angioplasty catheter to prevent restenosis: initial bench test results. Am J Cardiol 1997; 80 (8A): 26S

1997

 103. Kollum M, Kaiser S, Kinscherf R, Metz J, Kübler W, Hehrlein C: Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler Thromb Vasc Biol 1997; 91: 698-704

104. Hehrlein C, Kübler W: Advantages and limitations of radioactive stents. Sem Intervent Cardiol 1997; 2: 109-113

105. Hehrlein C, Bode C, Kübler W: Prävention der Restenose nach perkutaner transluminaler Koronarangioplastie (PTCA). Fibrinolyse 1997; 1: 9-12

106. Hehrlein C, Kovacs A, Löscher F, Seeger S, Wolf GK: Novel radioisotope coated angioplasty catheter to prevent restenosis: initial bench test results. Am J Cardiol 1997; 80 (8A): 26S 

1996

 107. Hehrlein C, Stintz M, Kinscherf R, Schlösser K, Friedrich L, Huttel E, Fehsenfeld P, Kübler W: Pure -particle emitting stents inhibit neointima formation in rabbits. Circulation 1996; 93: 641-645

108. Hehrlein C, Fehsenfeld, P: Radioactive Stents. In: Vascular Brachytherapy. 1st edition (eds. SB King, IR Crocker,RF Gould), Nucleotron B.V. 1996, pp 217-221

109. Hehrlein C: Balloon catheter to prevent restenosis. Patent WO 96221121 (1996) Beschichtungsverfahren eines Ballon-Katheters mit einem radioisotopenhaltigen Polymer ohne Plastizitätsverlust und radioaktive Kontamination.

110. Hehrlein C, Stintz M, Kinscherf R, Fehsenfeld P, Kübler W: Radioaktive Stents mit reiner Beta-Strahlung verhindern die Intimahyperplasie in vivo. Z Kardiol 1996; 85: Suppl 2: 147 111. Hehrlein C, Kaiser S, Kollum M, Kinscherf R, Metz J, Fritz P: External beam radiation fails to inhibit neointima formation in stented rabbit arteries. Circulation 1996; 94: Suppl 1:I-210 

1995

112. Hehrlein C, Thompson M, Chuang CH, Splinter R, Tuntelder JR, Littmann L, Svenson RH: Selective coagulation necrosis of canine adventitia and media induces extracellular matrix accumulation without neointima formation. Atherosclerosis 1995;

113: 109-115 113. Hehrlein C, Ritz E: The uraemic patient with small suggillations on the forehead. Nephrol Dial Transplant 1995; 10: 421-422

114. Hehrlein C, Zimmermann M, Ensinger W, Metz J, Kübler W: Influence of surface texture and charge on the biocompatibility of an endovascular stent. Coron Artery Dis 1995; 6: 581-586

115. Hehrlein C, Gollan C, Dönges K, Metz J, Riessen R, Fehsenfeld P, von Hodenberg E, Kübler W: Low-dose radioactive endovascular stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation 1995; 92: 1570-1575

116. Hehrlein C: How do AV fistulae lose function? The roles of haemodynamics, vascular remodelling, and intimal hyperplasia. Nephrol Dial Transplant 1995; 10: 1287-1289

117. Hehrlein C, Dönges K, Gollan C, Metz J, Fehsenfeld P: Low-dose radioactive Palmaz-Schatz stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. J Am Coll Cardiol 1995; Suppl 1: 9A

118. Hehrlein C, Metz J, Dönges K, Gollan C, Riessen R, Fehsenfeld P: Histomorphometrische, immuncytochemische und elektronenmikroskopische Analyse der Gefäßwand nach Implantation radioaktiver Stents mit geringer Dosisleistung in vivo. Z Kardiol 1995; 84: Suppl 1: 230

119. Hehrlein C, Gollan C, Dönges K, Metz J, Riessen R, Fehsenfeld P: Nieder- energetische, ionisierende Strahlung durch aktivierte Stents hemmt die Proliferation glatter Muskelzellen in vivo. Z Kardiol 1995; 84: Suppl 1: 142

120. Hehrlein C, Kaiser S, Kollum K, Kinscherf R, Fehsenfeld P: Effects of very lowdose endovascular irradiation via an activated guide-wire on neointima formation after stent implantation. Circulation 1995; 92: Suppl: I-146

121. Hehrlein C, Fehsenfeld P: Vascular implant and direct ion implantation process. Patent US 5947889 (1995): Verfahren zur direkten Ionen-Implantation von Radioistopen in metallische Stents.

122. Hehrlein C: Radioaktiver Ballonkatheter zur Prävention der Restenose. Patent DE 196 00 669 C2 (1995): Verfahren zur Umwandlung eines herkömmlichem Ballon-Katheters in einen radioaktiven Ballon-Katheter durch Beschichtung.

1994

120. Hehrlein C, Zimmermann M, Pill J, Metz J, Kübler W, von Hodenberg E: The role of elastic recoil after balloon angioplasty of rabbit arteries and its prevention by stent implantation.Eur Heart J 1994; 15: 277-280

121. Hehrlein C, Fehsenfeld P: Vascular Implant. Patent EP 0805703 (1994): Radioaktiver Stent und Herstellungsverfahren über Konversion von Metallionen in Radionuklide durch Beschuss mit Deuteronen.

123. Hehrlein C, Zimmermann M, Metz J, Fehsenfeld P, von Hodenberg E, Kübler W: Die Implantation von radioaktiven Stents verhindert die Intimahyperplasie im Kaninchen. Z Kardiol 1994; 83: Suppl 1: 139

124. Hehrlein C, Riessen R, Gollan C, Dönges C, Fehsenfeld P, von Hodenberg E: Arterial wall cell distribution after implantation of radioactive stents. Circulation 1994; 90: Part 2, Suppl 1: I-597

1993

125. Hehrlein C, Zimmermann M, Grunze M, Metz J, Wolf GK, von Hodenberg E: Metallische Stent-Beschichtungen. Z Kardiol 1993; 82: Suppl 1: 73 126. Hehrlein C, Zimmermann M , Grunze M, Metz J, Wolf GK, von Hodenberg E: Characteristics of metallically modified stents and their influence on neointima Formation in rabbits. Eur Heart J 1993; 14: Suppl 1: 321

127. Hehrlein C, Zimmermann M, Metz J, Fehsenfeld P, von Hodenberg E: Radioactive coronary stent implantation inhibits neointimal proliferation in non-atherosclerotic rabbits. Circulation 1993; 88: Suppl 1, I-651

128. Hehrlein C, Fehsenfeld P: Antiproliferativ wirkendes Gefäßimplantat. Patent DE 43 15 002 C1 (1993). Stent zur Verhinderung der Restenose nach Angioplastie.

1992

129. Hehrlein C, Svenson RH, McKusik AP, Chuang CH, Tuntelder JR, Tatsis GP, Littmann L, Thompson M: Thermal arterial injury and prostacyclin administration in dogs: Thrombotic and hyperplastic consequences. J Cardiovasc Surg 1992; 33: 366-371

130. Hehrlein C, Svenson RH, Kübler W: Eine Laser-Koagulation der Adventitia verursacht eine arterielle Hyperplasie ohne Neointima.Z Kardiol 1992; 80, Suppl 1: 30

131. Hehrlein C, ZImmermann M, von Hodenberg E, Metz J, Wolf GK: Metallic modification of stents and its impact on restenosis. Circulation 1992; 86: I-634

1991

132. Littmann L, Svenson RH, Tuntelder JR, Hehrlein C, Splinter R, Tatsis GP, Thompson M, Dezern K: Electrophysiologic characteristics of manifest and latent retrograde conduction in dogs. Am Heart J 1991; 121: 96-104

133. Littmann L, Svenson RH, Tomscanyi I, Hehrlein C, Gallagher JJ, Bharati S, Lev M, Splinter R, Tatsis GP, Tuntelder JR: Modification of atrioventricular nodal transmission properties by intraoperative Neodymium:YAG laser photocoagulation in dogs. J Am Coll Cardiol 1991; 17: 797-804

134. Hehrlein C, Splinter R, Littmann L, Tuntelder JR, Tatsis GP, Svenson RH: Influence of probe motion on laser probe temperature in circulating blood.Las Surg Med 1991; 11: 13-17

135. Hehrlein C, Chuang CH, Tuntelder JR, Tatsis GP, Littmann L, Svenson RH: Effects of vascular runoff on myointimal hyperplasia after mechanical or thermal arterial injury in dogs. Circulation 1991; 84: 884-890

136. Hehrlein C, Svenson RH: Thrombozytenadhäsion und myointimale Hyperplasie nach PGI2 -Gabe und thermischer Laserangioplastie am Hund. Z Kardiol 1991; 80: Suppl 3: 28

137. Hehrlein C, Svenson RH: Myointimale Proliferation als Ausdruck der Gefäßwandregeneration nach experimentellerLaser-oderBallon-Angioplastie.Klin Wochenschr 1991; 69: Suppl 23: 121 

1990

138. Bosse A, Hehrlein C, Mulch J: Das periphere Aneurysma spurium als Komplikation nach Gefäßrekonstruktion. Angio 1990; 4: 103-108

139. Hehrlein C, Chuang CH, Tuntelder JR, Splinter R, Littmann L, Svenson RH: Intimal hyperplasia after laser thermal angioplasty in canines with normal and reduced vascular runoff. Las Surg Med 1990; 9: Suppl 2: II-14

1988

140. Hehrlein C, Bosse A, Mulch J: Kombinierte Anwendung der Ultraschall- Dopplersonographie und der Duplex-Sonographie in der Beurteilung der Arteria carotis. Helvetia Chirurgica Acta 1988; 55: 439-443

1986 

141. Hehrlein C: Inauguraldissertation: Vergleichsstudie zwischen der konventionellen Angiographie, der Ultraschall-Doppler-Sonographie, der digitalen Subtraktionsangiographie und dem Operationsbefund an der A. carotis interna.

1983

142. Zeitler E, Seyerth W, Berger G, Hehrlein C, Raithel D: Diagnostic reliability of digital subtraction angiography in the portrayal of the extracranial carotidcarotid artery disease. In: Contrast Media in Digital Radiography, Excerpta Medica, Berlin 1983; pp 154-162